Organization
Dallas
12 abstracts
Abstract
The genomic and transcriptomic landscapes of chemotherapy naïve vs post-chemotherapy germ cell tumors.Org: University of California San Diego Health, CanSino Biologics, La Jolla, CA, UT Southwestern Medical Center, Txinno Bioscience,
Abstract
Unveiling the interplay of social factors in cancer survivorship: A comprehensive social determinants of health (SDOH) profile analysis.Org: Tsinghua University, Beijing InnoCare Pharma Tech, China National Biotec Group, University of Oklahoma Health Sciences Center, Oklahoma City,
Abstract
Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part.Org: Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, University of Chicago, Chicago, IL, Department of Medicine, Division of Hematology and Oncology, The Medical College of Wisconsin, Milwaukee, WI, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, Mary Crowley Cancer Research, Dallas, TX, AdventHealth Cancer Institute, Orlando, FL, Sarah Cannon Research Institute, Nashville, TN, St. Jude Crosson Cancer Institute/Providence Medical Foundation, Fullerton, CA, Fort Wayne Medical Oncology - West Jefferson Office, Fort Wayne, IN, Scholar Rock Inc., Cambridge, MA, Scholar Rock, Cambridge, MA, The University of Texas MD Anderson Cancer Center, Houston, TX, University of Michigan, University of Chicago, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, Division of Hematology and Oncology,
Abstract
Analyzing megestrol prescribing patterns in the Medicare cancer population in a community oncology network.Org: The US Oncology Network, The Woodlands, Txinno Bioscience, Dallas,
Abstract
Safety and efficacy of osimertinib plus consolidative stereotactic ablative radiation (SABR) in advanced EGFR mutant non-small cell lung cancer (NSCLC): Results from a multi-center phase II trial.Org: UT Southwestern Medical Center, Dallas, City of Hope National Comprehensive Cancer Center, Duarte, CA, Memorial Sloan Kettering Cancer Center,
Abstract
Tracking uncertainty in germline genetic testing for hereditary cancer syndromes: Sources, attributes, and resolution of variants of uncertain significance in over 1 million individuals.Org: UT Southwestern Medical Center, Dallas, Txinno Bioscience, Invitae, Fort Lauderdale,
Abstract
Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260 study.Org: School of Medicine, Zhejiang University, Hangzhou, China, Yale University, New Haven, CTI BioPharma, Keck School of Medicine of the University of Southern California,
Abstract
A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors.Org: Mary Crowley Cancer Research Center, Dallas, Next Oncology Virginia and Virginia Cancer Specialists, San Antonio Breast Cancer Symposium, Northwell Health Cancer Institute,
Abstract
The impact of a cancer-specific novel therapy adjustment (NTA) in Medicare value-based care programs: A simulation exercise.Org: US Oncology Network, Dallas, Txinno Bioscience, McKesson, Denver, CO,
Abstract
Aligning NCCN criteria with testing workflows using a novel database application (Criterion).Org: Nexgen Precision, Dallas, Txinno Bioscience, Nexgen Onc,
Abstract
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, SEQUENTIAL-DOSE STUDY OF THE SAFETY OF APRATASTAT (TMI-005), A NOVEL ORAL DUAL INHIBITOR OF TNF-ALPHA-CONVERTING ENZYME/METALLOPROTEINASE, IN PATIENTS WITH RHEUMATOID ARTHRITIS ON A BACKGROUND OF METHOTREXAOrg: Research Center for Health Policy and Economics, Radiant Research, Dallas, Altoona Center for Clinical Research, Duncansville, Duncansville,
Abstract
A PROSPECTIVE RANDOMIZED 13-WEEK STUDY EVALUATING THE EFFICACY OF LUMIRACOXIB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEEOrg: University of Texas Southwestern Medical Center, Radiant Research Dallas, Dallas, Miami Research Associates, Miami Cancer Institute - Baptist Health South Florida,